|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02315 BIOCYTOGEN-B
Nominal 
24.700 -1.100 (-4.264%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 620,963 | 51.270% | 980,454 | 716,912 | 533,881 | 354,555 |
| Cost of Sales | (159,014) | 51.433% | (218,935) | (210,878) | (142,131) | (107,115) |
| Gross Profit | 461,949 | 51.214% | 761,519 | 506,034 | 391,750 | 247,440 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 20,796 | 220.777% | 14,195 | 4,879 | 3,923 | 9,812 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (11,856) | 30.501% | (29,753) | (10,027) | (14,770) | (402) | |
| Profit / (Loss) before Taxation | 59,620 | -- | 42,940 | (380,156) | (601,353) | (545,643) | |
| Taxation | (11,621) | 223.165% | (9,403) | (2,796) | (804) | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 5 | 1 | 212 | 67 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 47,999 | -- | 33,542 | (382,951) | (601,945) | (545,576) | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 33,566 | -31.887% | 85,780 | 89,686 | 53,972 | 26,919 |
| Depreciation & Amortisation | 85,099 | -0.424% | 169,181 | 189,982 | 174,099 | 128,097 |
| Directors' Emoluments | -- | -- | 8,422 | 6,331 | 3,672 | 7,041 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 12.000 | -- | 8.000 | -96.000 | -158.000 | -151.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.531 | (0.192) | (0.796) | (1.009) |
| NBV per share ($) | 2.233 | -- | 2.088 | 1.968 | 2.870 | -- |
| Remarks: | Real time quote last updated: 11/09/2025 17:15 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 47,999 |
| %Change | -- |
| EPS / (LPS) | RMB 0.120 |
| NBV Per Share (¥) | RMB 2.233 |